U.S. FDA approves Alexion Pharma’s rare blood disorder drug

The U.S. Food and Drug Administration on Friday approved Alexion Pharmaceuticals Inc’s rare blood disorder drug Ultomiris, nearly two months earlier than expected.

The drug’s sales are expected to reach $1.66 billion by 2022, according to IBES data from Refinitiv.

Ultomiris was approved to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare, acquired, life-threatening disorder in which red blood cells are prematurely destroyed.

Alexion already markets treatments for rare diseases, and its drug Soliris is approved to treat PNH.

The FDA had set Feb. 18 as the date for a decision.

  • Related Posts

    Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

    New Delhi:  Aurobindo Pharma Ltd on Tuesday said it has set April 23 as the opening date for its Rs 800 crore buyback offer. The closing date for the buyback…

    Boehringer Ingelheim launches AI centre for pharma research in London

    Bengaluru: German drugmaker Boehringer Ingelheim is launching a ​centre for artificial ​intelligence and machine learning in London, it said ​on Monday, as it seeks to expand its AI capabilities in…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

    Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

    Boehringer Ingelheim launches AI centre for pharma research in London

    Boehringer Ingelheim launches AI centre for pharma research in London

    Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

    Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid